ArticleSubstance use & misuse2022
Lessons from the First Wave of COVID-19 for Improved Medications for Opioid Use Disorder (MOUD) Treatment: Benefits of Easier Access, Extended Take Homes, and New Delivery Modalities.
Open access · greenAbstract read
In one paragraph
Article in Substance use & misuse, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
7.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Patient and provider experiences with opioid use disorder care delivered via telehealth: A systematic mixed-studies review.Drug and alcohol dependence · 2025Pooled it
- The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review.Substance abuse treatment, prevention, and policy · 2023Pooled it
- Lessons from COVID-19 for improving delivery of medications for opioid use disorder in future pandemic events: results from a Puerto Rico Delphi consensus panel.Harm reduction journal · 2026Article
- Narrative Review of Opioid Use Disorder Treatment Changes During the COVID-19 Pandemic and Their Impact on American Indian/Alaska Native Communities.Nursing open · 2026Review
- Impact of COVID-19 lockdown on methadone and buprenorphine prescriptions in England primary cares: an interrupted time series analysis.Harm reduction journal · 2025Article
- Investigating heterogeneous effects of an expanded methadone access policy with opioid treatment program retention: a Rhode Island population-based retrospective cohort study.American journal of epidemiology · 2025Article
- What is necessary for implementation science to actually improve the state of addiction treatment and research?Journal of substance use and addiction treatment · 2025Article
- Patient and clinician experiences with the implementation of telemedicine and related adaptations in office-based buprenorphine treatment during the COVID-19 pandemic: a qualitative study.Addiction science & clinical practice · 2025Article
- Equal Access, Equal Outcomes: Telehealth Utilization Around the COVID-19 Pandemic among People Living with HIV and Opioid Use Disorder in the Deep South.AIDS and behavior · 2025Article
- Patient and Prescriber characteristics associated with return to daily-dispense methadone: A multilevel cohort study.PLOS mental health · 2025Article
- "If it wasn't for them, I don't think I would be here": experiences of the first year of a safer supply program during the dual public health emergencies of COVID-19 and the drug toxicity crisis.Harm reduction journal · 2024Article
- Stigma, Mental Health, and Health care Use Among Rural Sexual and Gender Minority Individuals.Health education & behavior : the official publication of the Society for Public Health Education · 2024Article
- "It didn't hurt me": patients' and providers' perspectives on unsupervised take-home doses, drug diversion, and overdose risks in the provision of medication for opioid use disorder during COVID-19 in San Juan, Puerto Rico.Harm reduction journal · 2024Article
- Patient and Clinician Experiences with the Implementation of Telemedicine and Related Adaptations in Office-Based Buprenorphine Treatment During the COVID-19 Pandemic: A Qualitative Study.Research square · 2024Article
- "They make it too hard and too many hoops to jump": system and organizational barriers to drug treatment during epidemic rates of opioid overdose.Harm reduction journal · 2024Article
- Loss, liberation, and agency: Patient experiences of methadone treatment at opioid treatment programs during the COVID-19 pandemic.Journal of substance use and addiction treatment · 2024Article
- Article
- Retention and critical outcomes among new methadone maintenance patients following extended take-home reforms: a retrospective observational cohort study.Lancet regional health. Americas · 2023Article
- Developing a Theoretically Informed Implementation Model for Telemedicine-Delivered Medication for Opioid Use Disorder: Qualitative Study With Key Informants.JMIR mental health · 2023Article
- Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey.Harm reduction journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Suzan M WaltersSchool of Global Public Health, New York University, New York, New York, USA.ORCID 0000-0002-2975-2893
David C PerlmanCenter for Drug Use and HIV/HCV Research, NYU School of Global Public Health, New York, New York, USA.
Honoria GuarinoCenter for Drug Use and HIV/HCV Research, NYU School of Global Public Health, New York, New York, USA.
Pedro Mateu-GelabertCenter for Drug Use and HIV/HCV Research, NYU School of Global Public Health, New York, New York, USA.
David FrankSchool of Global Public Health, New York University, New York, New York, USA.ORCID 0000-0003-3304-3237
City University of New York · USNew York University · USIcahn School of Medicine at Mount Sinai · US
Funding
Transdisciplinary Theoretical Svnthesis and Development CoreP30DA011041 · NIDA · NEW YORK UNIVERSITY · PI Holly Hagan, Courtney McKnight · 1998 to 2026
$38.9MBEHAVIORAL SCI TRAINING IN DRUG ABUSE RESEARCHT32DA007233 · NIDA · PUBLIC HEALTH SOLUTIONS · PI GOLDSAMT, LLOYD A · 1985 to 2023
$20.2MIntersectional Stigma Experiences, Pre-exposure Prophylaxis (PrEP), and Other Service Use Among People Who Inject DrugsK01DA053159 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WALTERS, SUZAN M · 2021 to 2025
$927kNIDA NIH HHS K01 DA053159NIDA NIH HHS P30 DA011041NIDA NIH HHS T32 DA007233
Abstract
PubMed holds no abstract for this paper.
Indexed as
BuprenorphineCOVID-19 Drug TreatmentOpioid-Related DisordersAnalgesics, OpioidHumansMethadoneOpiate Substitution TreatmentPharmaceutical PreparationsUnited StatesAnalgesics, OpioidBuprenorphineMethadonePharmaceutical PreparationsCOVID-19medication deliveriesMOUDtelehealth
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.